Silverback Retained Earnings from 2010 to 2025

SPRY Stock

12.57 0.39 3.20%

Silverback Therapeutics Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Silverback Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2010-12-31

Previous Quarter

-118.2 M

Current Value

-112.3 M

Quarterly Volatility

27.5 M

Credit Downgrade

Yuan Drop

Covid

Check Silverback Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silverback Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.4 K, Other Operating Expenses of 81.6 M or Research Development of 20.8 M, as well as many indicators such as Price To Sales Ratio of 16.4 K, Dividend Yield of 0.0 or PTB Ratio of 2.14. Silverback financial statements analysis is a perfect complement when working with Silverback Therapeutics Valuation or Volatility modules.

Check out the analysis of Silverback Therapeutics Correlation against competitors.

For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.

Latest Silverback Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Silverback Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Silverback Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Silverback Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (131.3 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Silverback Retained Earnings Regression Statistics

	Arithmetic Mean	(71,301,048)
	Geometric Mean	66,288,994
	Coefficient Of Variation	(38.57)
	Mean Deviation	19,184,197
	Median	(63,787,000)
	Standard Deviation	27,500,867
	Sample Variance	756.3T
	Range	109.3M
	R-Value	(0.49)
	Mean Square Error	613.5T
	R-Squared	0.24
	Significance	0.05
	Slope	(2,846,497)
	Total Sum of Squares	11344.5T

Silverback Retained Earnings History

	2025	-112.3 M
	2024	-118.2 M
	2023	-131.3 M
	2022	-76.9 M
	2021	-42.3 M
	2020	-22 M

Other Fundumenentals of Silverback Therapeutics

Retained Earnings Total Equity

Silverback Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Capital Surpluse	Intangible Assets
Total Assets		0.93	-0.87	-0.72	-0.79	-0.39	1.0	-0.84	0.92	-0.92	-0.89	0.87	0.93	0.9	-0.93	1.0	-0.93	0.64	-0.4	-0.4
Total Stockholder Equity	0.93		-0.79	-0.82	-0.78	-0.57	0.93	-0.81	1.0	-0.92	-0.84	0.88	1.0	0.82	-1.0	0.95	-1.0	0.56	-0.65	-0.65
Net Debt	-0.87	-0.79		0.39	0.66	0.17	-0.87	0.78	-0.75	0.8	0.78	-0.72	-0.79	-0.74	0.77	-0.86	0.77	-0.64	0.25	0.25
Retained Earnings	-0.72	-0.82	0.39		0.52	0.68	-0.72	0.48	-0.84	0.75	0.65	-0.72	-0.82	-0.65	0.84	-0.76	0.84	-0.38	0.57	0.57
Accounts Payable	-0.79	-0.78	0.66	0.52		0.09	-0.8	0.98	-0.81	0.88	0.86	-0.55	-0.8	-0.84	0.79	-0.79	0.79	-0.74	0.59	0.59
Total Liab	-0.39	-0.57	0.17	0.68	0.09		-0.38	0.07	-0.56	0.23	0.05	-0.76	-0.56	-0.08	0.6	-0.43	0.6	0.33	0.36	0.36
Total Current Assets	1.0	0.93	-0.87	-0.72	-0.8	-0.38		-0.85	0.92	-0.93	-0.89	0.87	0.93	0.9	-0.93	1.0	-0.93	0.65	-0.4	-0.4
Short Term Debt	-0.84	-0.81	0.78	0.48	0.98	0.07	-0.85		-0.82	0.9	0.89	-0.59	-0.82	-0.87	0.8	-0.84	0.8	-0.77	0.52	0.52
Net Tangible Assets	0.92	1.0	-0.75	-0.84	-0.81	-0.56	0.92	-0.82		-0.93	-0.85	0.86	1.0	0.83	-0.99	0.95	-0.99	0.58	-0.68	-0.68
Current Deferred Revenue	-0.92	-0.92	0.8	0.75	0.88	0.23	-0.93	0.9	-0.93		0.98	-0.68	-0.93	-0.95	0.91	-0.94	0.91	-0.83	0.6	0.6
Long Term Debt	-0.89	-0.84	0.78	0.65	0.86	0.05	-0.89	0.89	-0.85	0.98		-0.57	-0.84	-0.98	0.82	-0.89	0.82	-0.91	0.54	0.54
Net Receivables	0.87	0.88	-0.72	-0.72	-0.55	-0.76	0.87	-0.59	0.86	-0.68	-0.57		0.88	0.6	-0.9	0.88	-0.9	0.2	-0.35	-0.35
Net Invested Capital	0.93	1.0	-0.79	-0.82	-0.8	-0.56	0.93	-0.82	1.0	-0.93	-0.84	0.88		0.82	-1.0	0.96	-1.0	0.57	-0.65	-0.65
Short Long Term Debt	0.9	0.82	-0.74	-0.65	-0.84	-0.08	0.9	-0.87	0.83	-0.95	-0.98	0.6	0.82		-0.8	0.9	-0.8	0.88	-0.5	-0.5
Capital Stock	-0.93	-1.0	0.77	0.84	0.79	0.6	-0.93	0.8	-0.99	0.91	0.82	-0.9	-1.0	-0.8		-0.96	1.0	-0.53	0.62	0.62
Net Working Capital	1.0	0.95	-0.86	-0.76	-0.79	-0.43	1.0	-0.84	0.95	-0.94	-0.89	0.88	0.96	0.9	-0.96		-0.96	0.64	-0.45	-0.45
Common Stock	-0.93	-1.0	0.77	0.84	0.79	0.6	-0.93	0.8	-0.99	0.91	0.82	-0.9	-1.0	-0.8	1.0	-0.96		-0.53	0.62	0.62
Property Plant Equipment	0.64	0.56	-0.64	-0.38	-0.74	0.33	0.65	-0.77	0.58	-0.83	-0.91	0.2	0.57	0.88	-0.53	0.64	-0.53		-0.42	-0.42
Capital Surpluse	-0.4	-0.65	0.25	0.57	0.59	0.36	-0.4	0.52	-0.68	0.6	0.54	-0.35	-0.65	-0.5	0.62	-0.45	0.62	-0.42		1.0
Intangible Assets	-0.4	-0.65	0.25	0.57	0.59	0.36	-0.4	0.52	-0.68	0.6	0.54	-0.35	-0.65	-0.5	0.62	-0.45	0.62	-0.42	1.0

Click cells to compare fundamentals

About Silverback Therapeutics Financial Statements

Silverback Therapeutics investors use historical fundamental indicators, such as Silverback Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Silverback Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-118.2 M	-112.3 M
Retained Earnings Total Equity	-69.2 M	-72.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
V	Visa Class A
C	Citigroup

Additional Tools for Silverback Stock Analysis

When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC